• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Surefire Medical touts infusion tech in liver cancer trial

June 8, 2017 By Sarah Faulkner

Surefire MedicalSurefire Medical touted data today from a retrospective analysis of 85 bridge-to-transplant liver cancer patients treated with transarterial chemoembolization.

The data showed that therapy delivered using the Surefire infusion system yielded an 80% complete response in 1 treatment compared to 52% with a standard endhole microcatheter. The analysis also demonstrated a lower recurrence rate of liver cancer at 1 month for patients that used Surefire’s technology instead of a conventional microcatheter.

All of the study’s participants were diagnosed with hepatocellular carcinoma and were eligible for a liver transplant.

In 1 subanalysis, researchers found that the use of Surefire’s infusion system improved tumor uptake. 89% of chemo beads were delivered to the tumor in patients that used the Surefire technology compared to 55% of beads in the group that used a standard microcatheter procedure.

Another review found that the tumor necrosis rate for Surefire procedures was 89% versus 56% for the microcatheter approach.

“This study of bridge-to-transplant patients with HCC provides further evidence to suggest that Surefire may be a more effective tool to downstage patients for transplant when compared with a standard endhole microcatheter,” transplant hepatologist Dr. Lance Stein said in prepared remarks. “As evidenced in this and previous clinical studies, the use Surefire technology in embolization procedures optimizes penetration of therapy in tumors, which potentially increases complete response rates and spares healthy tissue. The data also showed consistently high tumor necrosis was achieved with the Surefire.”

Westminster, Colo.-based Surefire Medical has 5 other ongoing clinical trials of its technology, which combines a microcatheter with an expandable tip that boosts tumor uptake while protecting healthy tissue, according to the company.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology Tagged With: surefiremedical

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS